PMC:7545501 / 30824-32034 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T29","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"T30","span":{"begin":252,"end":260},"obj":"Disease"},{"id":"T31","span":{"begin":652,"end":668},"obj":"Disease"},{"id":"T32","span":{"begin":1114,"end":1122},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0025481"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In light of the faults laid bare by COVID-19, we have already begun reexamining indicators of leadership, trust in government and political risk. The next iteration of the GHS Index, slated to release in 2021, will also emphasise other indicators that COVID-19 has shown to be vital for pandemic response, particularly those capturing state capacity to sustain societal functioning during a major outbreak. At present, we tentatively anticipate adding metrics of government effectiveness, as well as measures examining contact tracing and data sharing. We also anticipate revising several existing questions and adding over 20 new questions addressing zoonotic disease spillover events, scaling of testing capacities, abilities to test for novel pathogens, non-pharmaceutical interventions, private sector participation in exercises, risk communication, mis-information and disinformation, trade and travel, health security financing, social cohesion, illicit activities carried out by non-state actors, supply chains for medical supplies, laboratory supplies and medical countermeasures. Drawing further from the COVID-19 experience, we may also revisit weighting schemes for select categories and indicators."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T99","span":{"begin":261,"end":264},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T100","span":{"begin":389,"end":390},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T101","span":{"begin":698,"end":705},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T102","span":{"begin":731,"end":735},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T103","span":{"begin":960,"end":970},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"In light of the faults laid bare by COVID-19, we have already begun reexamining indicators of leadership, trust in government and political risk. The next iteration of the GHS Index, slated to release in 2021, will also emphasise other indicators that COVID-19 has shown to be vital for pandemic response, particularly those capturing state capacity to sustain societal functioning during a major outbreak. At present, we tentatively anticipate adding metrics of government effectiveness, as well as measures examining contact tracing and data sharing. We also anticipate revising several existing questions and adding over 20 new questions addressing zoonotic disease spillover events, scaling of testing capacities, abilities to test for novel pathogens, non-pharmaceutical interventions, private sector participation in exercises, risk communication, mis-information and disinformation, trade and travel, health security financing, social cohesion, illicit activities carried out by non-state actors, supply chains for medical supplies, laboratory supplies and medical countermeasures. Drawing further from the COVID-19 experience, we may also revisit weighting schemes for select categories and indicators."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T22","span":{"begin":761,"end":775},"obj":"Chemical"}],"attributes":[{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"}],"text":"In light of the faults laid bare by COVID-19, we have already begun reexamining indicators of leadership, trust in government and political risk. The next iteration of the GHS Index, slated to release in 2021, will also emphasise other indicators that COVID-19 has shown to be vital for pandemic response, particularly those capturing state capacity to sustain societal functioning during a major outbreak. At present, we tentatively anticipate adding metrics of government effectiveness, as well as measures examining contact tracing and data sharing. We also anticipate revising several existing questions and adding over 20 new questions addressing zoonotic disease spillover events, scaling of testing capacities, abilities to test for novel pathogens, non-pharmaceutical interventions, private sector participation in exercises, risk communication, mis-information and disinformation, trade and travel, health security financing, social cohesion, illicit activities carried out by non-state actors, supply chains for medical supplies, laboratory supplies and medical countermeasures. Drawing further from the COVID-19 experience, we may also revisit weighting schemes for select categories and indicators."}

{"project":"LitCovid-sentences","denotations":[{"id":"T136","span":{"begin":0,"end":145},"obj":"Sentence"},{"id":"T137","span":{"begin":146,"end":406},"obj":"Sentence"},{"id":"T138","span":{"begin":407,"end":552},"obj":"Sentence"},{"id":"T139","span":{"begin":553,"end":1088},"obj":"Sentence"},{"id":"T140","span":{"begin":1089,"end":1210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In light of the faults laid bare by COVID-19, we have already begun reexamining indicators of leadership, trust in government and political risk. The next iteration of the GHS Index, slated to release in 2021, will also emphasise other indicators that COVID-19 has shown to be vital for pandemic response, particularly those capturing state capacity to sustain societal functioning during a major outbreak. At present, we tentatively anticipate adding metrics of government effectiveness, as well as measures examining contact tracing and data sharing. We also anticipate revising several existing questions and adding over 20 new questions addressing zoonotic disease spillover events, scaling of testing capacities, abilities to test for novel pathogens, non-pharmaceutical interventions, private sector participation in exercises, risk communication, mis-information and disinformation, trade and travel, health security financing, social cohesion, illicit activities carried out by non-state actors, supply chains for medical supplies, laboratory supplies and medical countermeasures. Drawing further from the COVID-19 experience, we may also revisit weighting schemes for select categories and indicators."}

{"project":"LitCovid-PubTator","denotations":[{"id":"102","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"103","span":{"begin":252,"end":260},"obj":"Disease"},{"id":"104","span":{"begin":652,"end":668},"obj":"Disease"},{"id":"105","span":{"begin":1114,"end":1122},"obj":"Disease"}],"attributes":[{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"MESH:C000657245"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"MESH:C000657245"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:D015047"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In light of the faults laid bare by COVID-19, we have already begun reexamining indicators of leadership, trust in government and political risk. The next iteration of the GHS Index, slated to release in 2021, will also emphasise other indicators that COVID-19 has shown to be vital for pandemic response, particularly those capturing state capacity to sustain societal functioning during a major outbreak. At present, we tentatively anticipate adding metrics of government effectiveness, as well as measures examining contact tracing and data sharing. We also anticipate revising several existing questions and adding over 20 new questions addressing zoonotic disease spillover events, scaling of testing capacities, abilities to test for novel pathogens, non-pharmaceutical interventions, private sector participation in exercises, risk communication, mis-information and disinformation, trade and travel, health security financing, social cohesion, illicit activities carried out by non-state actors, supply chains for medical supplies, laboratory supplies and medical countermeasures. Drawing further from the COVID-19 experience, we may also revisit weighting schemes for select categories and indicators."}